Charles Schwab Investment Management Inc. Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA

Key Points

• Charles Schwab Investment Management Inc. has reduced its stake in Vanda Pharmaceuticals by 14.8% to approximately $2.18 million, owning about 0.81% of the company after selling 82,581 shares in the first quarter.
• Vanda Pharmaceuticals reported a loss of ($0.46) per share for the last quarter, missing estimates, and had revenues of $52.59 million, falling short of the consensus estimate of $54.77 million.
• Equities analysts have mixed ratings for Vanda, with one downgrading to a "strong sell" and others maintaining "buy" ratings with a range of price targets, reflecting a consensus target of $16.50.

Charles Schwab Investment Management Inc. decreased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 14.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 475,865 shares of the biopharmaceutical company's stock after selling 82,581 shares during the period. Charles Schwab Investment Management Inc. owned 0.81% of Vanda Pharmaceuticals worth $2,184,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of VNDA. Quantinno Capital Management LP bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at approximately $48,000. Linden Thomas Advisory Services LLC purchased a new stake in Vanda Pharmaceuticals during the first quarter worth $49,000. ProShare Advisors LLC boosted its position in Vanda Pharmaceuticals by 32.4% during the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company's stock valued at $90,000 after acquiring an additional 4,599 shares in the last quarter. Bailard Inc. purchased a new position in shares of Vanda Pharmaceuticals in the 1st quarter valued at $103,000. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Vanda Pharmaceuticals by 17.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock worth $107,000 after acquiring an additional 3,370 shares in the last quarter. Hedge funds and other institutional investors own 88.14% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on VNDA. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, August 21st. Wall Street Zen lowered shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 2nd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. Based on data from MarketBeat, Vanda Pharmaceuticals currently has an average rating of "Strong Buy" and an average price target of $16.50.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA traded down $0.08 during mid-day trading on Thursday, hitting $4.64. The stock had a trading volume of 575,868 shares, compared to its average volume of 430,313. The firm has a market cap of $274.18 million, a PE ratio of -4.11 and a beta of 0.74. The company has a 50 day moving average of $4.64 and a two-hundred day moving average of $4.54. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $5.55.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.12). The firm had revenue of $52.59 million for the quarter, compared to analysts' expectations of $54.77 million. Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $4.59, for a total value of $32,130.00. Following the transaction, the director owned 97,082 shares in the company, valued at approximately $445,606.38. This represents a 6.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is currently owned by corporate insiders.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.